EPISODE · Sep 20, 2024 · 3 MIN
EP18 - Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression
from Women and Mental Health · host Andrew MacQuoid
Brexanolone, the first FDA-approved drug specifically for postpartum depression, emerged from decades of NIMH-supported research. It was developed based on understanding how allopregnanolone, a hormone that decreases after childbirth, influences mood. Brexanolone restores this hormone’s levels, offering rapid relief from postpartum depression symptoms.
What this episode covers
Brexanolone, the first FDA-approved drug specifically for postpartum depression, emerged from decades of NIMH-supported research. It was developed based on understanding how allopregnanolone, a hormone that decreases after childbirth, influences mood. Brexanolone restores this hormone’s levels, offering rapid relief from postpartum depression symptoms.
NOW PLAYING
EP18 - Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m